How a clinical-stage antiviral company turned a pivotal data readout into a value proposition the market could price

When positive Phase 2b results landed, investors could finally price what they saw, and within months a stock in the teens became a $9.2 billion Merck acquisition.

Challenge Pivotal readout → investable value proposition

Domain Antiviral · Influenza prophylaxis

Stage Public (NASDAQ: CDTX) · Ph 2b → Ph 3

Audience Investors · analysts · acquirers

Diagram of CD388, a drug-Fc conjugate arraying multiple copies of zanamivir on an engineered human antibody Fc fragment with flexible linkers.

CD388, a drug-Fc conjugate (DFC) — the asset at the center of the value proposition.

The Science

CD388 is a drug-Fc conjugate: multiple copies of zanamivir, a neuraminidase inhibitor, stably conjugated to an engineered human antibody Fc fragment for extended half-life.

It blocks viral release at a conserved binding pocket, so activity holds across seasonal and pandemic strains, including H5N1 and variants resistant to neuraminidase inhibitors. Because protection does not depend on mounting an immune response, a single seasonal dose can protect immunocompromised and other high-risk patients that vaccines and short-acting antivirals leave exposed.

Mechanism of action: CD388 binds neuraminidase and prevents cleavage of budded influenza viruses, blocking viral release from the infected cell. — Mechanism of action — CD388 prevents viral release from the infected cell by multi-contact blocking of neuraminidase.

CD388 (65–70 kDa) is much smaller than an antibody (150 kDa), achieving roughly 34% lung penetration versus 2–17% for antibodies, and binds a conserved pocket unaffected by seasonal mutations. — Better tissue penetration than vaccine-induced antibodies.

CD388 and vaccine-induced antibodies bind two spatially different locations on the flu virus, so CD388 can complement influenza vaccines without interfering with HAI responses. — Complements influenza vaccines — distinct, conserved binding site.

The Challenge

A genuinely new drug class is easy to mishear.

CD388 could read as "just another flu shot" or a niche antiviral, when it was something larger: non-vaccine, single-dose, strain-agnostic prophylaxis for a high-risk population numbering over 50 million in the US alone. The Phase 2b NAVIGATE top-line was due in June 2025, with an Investor Day on May 22. At a data inflection point, attention is finite and the narrative is priced in real time — a value proposition investors couldn't grasp quickly would leave the science, and the valuation, underread.

The Work

The data would speak for one quarter; the value proposition had to outlast it.

Cognition built the investor communication and Investor Day strategy as a single arc, timed to the June readout. The move: shift the story from what CD388 is to what it changes , a once-a-season answer for the patients existing tools fail.

We restructured the data narrative so the mechanism, the unmet need, and the commercial logic resolved into one legible thesis a non-specialist investor could hold and repeat, consistent from the data drop through Investor Day and analyst scrutiny. This is investor relations communication designed for the room where the decision gets made.

The Outcome

The science earned the result; the value proposition was legible when it mattered most.

Cidara Therapeutics (NASDAQ: CDTX) 2025 closing price: in the teens before the June 2025 Phase 2b readout, climbing past $100, then jumping to about $221.50 on Merck's roughly $9.2B acquisition at a 109% premium.

$9.2B

Merck agreed to acquire Cidara — $221.50 / share, a 109% premium (Nov 2025; closing early 2026).

Teens → ~$220

CDTX, in the teens a year earlier, changed hands near $220 by December — a more-than-tenfold move as specialist investors built positions.

Ph 3

NAVIGATE met all primary and secondary endpoints; FDA Breakthrough Therapy & Fast Track; advanced into Phase 3.

Figures reflect publicly reported events.

The takeaway

At a data inflection point, the science makes the case. A value proposition investors can price is what turns that case into a valuation. Clarity is not decoration; it is leverage.

Related proof

The same craft, other rooms.

See the capability →

The unbranded KnowMRD education system — brochures, case studies and clinical data summaries

MRD diagnostics · Medical Affairs

Building clinical belief in a new category of cancer testing.

Efzofitimod — structural rendering of the engineered Fc-fusion protein

Sarcoidosis · SVP

Turning a missed endpoint into a focused, data-defined clinical case.

Have a readout the market needs to price correctly?

Start a conversation →

Explore

All work→ Investor Relations→ Science Value Articulation→